Evidence map›Paper›PMID 37889388›Full record

ArticleDermatology and therapy2023

Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries.

Sergio Vañó-Galván, Ulrike Blume-Peytavi, Paul Farrant, Pascal Reygagne, Erin Johansson, Catherine Reed, Simran Marwaha, Frederick Durand, Bianca Maria Piraccini

Open access · goldAbstract read
In one paragraph

Article in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Psychosocial and mental impact of alopecia areata: Analysis of the Danish Skin Cohort.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Article
  10. Emotional burden and current management practices in pediatric alopecia areata: An online survey among physicians.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
    Article
  11. Thyroid Dysfunction and Alopecia Areata: A Genetic Prediction Causality Analysis Study.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
  12. Article
  13. Article
  14. Estimation of health utility values for alopecia areata.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Article
  15. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 6 countries.

Sergio Vañó-GalvánRamón y Cajal University Hospital, University of Alcala, Madrid, Spain.ORCID http://orcid.org/0000-0003-2773-7494
Ulrike Blume-PeytaviDepartment of Dermatology, Venerology and Allergology, Charité-Universitätsmedizin, Berlin, Germany.ORCID http://orcid.org/0000-0003-3528-3752
Paul FarrantDepartment of Dermatology, Brighton General Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.ORCID http://orcid.org/0000-0001-9695-0884
Pascal ReygagneCentre Sabouraud, Hôpital Saint-Louis, Paris, France.ORCID http://orcid.org/0000-0002-6062-2122
Erin JohanssonEli Lilly and Company, Indianapolis, IN, USA.
Catherine ReedEli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-4150-4569
Simran MarwahaAdelphi Real World, Macclesfield, Cheshire, UK.ORCID http://orcid.org/0000-0003-0380-0372
Frederick DurandEli Lilly and Company, Indianapolis, IN, USA.
Bianca Maria PiracciniDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni 15, 40138, Bologna, Italy. biancamaria.piraccini@unibo.it.ORCID http://orcid.org/0000-0001-6537-9689
Eli Lilly (United States) · USAdelphi Group (United Kingdom) · GBAzienda USL di Bologna · ITBrighton General Hospital · GBCharité - Universitätsmedizin Berlin · DELaboratoire Dr Renaud · FRUniversidad de Alcalá · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlopecia areata (AA) can negatively affect quality of life (QoL) and is associated with increased prevalence of anxiety and depression (vs people without AA). This study compared physician-assessed and patient self-rated severity of AA in a European sample and described the patient-reported burden of AA stratified by physician-assessed severity.

methodsReal-world data were collected from the Adelphi Real World AA Disease Specific Programme™, a retrospective point-in-time cross-sectional survey of dermatologists and their adult patients with AA in five European countries (France, Germany, Italy, Spain, UK). Physicians provided clinical data and an AA severity assessment, according to their own definition of 'mild', 'moderate' and 'severe'. Patients were invited to provide their perception of AA severity and completed patient-reported outcome (PRO) questionnaires, including Skindex-16 for AA (Skindex-16 AA), EuroQol-5-dimension questionnaire 5-level (EQ-5D-5L), Hospital Anxiety and Depression Scale and the Work Productivity and Activity Impairment Questionnaire.

resultsData for 2083 patients were collected by 239 physicians; 561 of these patients completed PRO questionnaires. In 78.5% of cases with available data (N = 549), there was alignment between patient and physician-rated AA severity (severity was rated higher by physicians in 15.7% of cases, by patients in 5.8% of cases). Data from all PRO instruments showed an increase in patient-reported burden and work and activity impairment with increasing physician-rated AA severity. For the Skindex-16 AA, the Emotions scale had the worst scores; anxiety/depression was the EQ-5D-5L dimension with the highest percentages of patients reporting any perceived problem.

conclusionsThese data highlight the significant impact that AA can have beyond hair loss, especially for patients with severe AA. There was substantial physician-patient alignment on severity assessment. Higher physician-rated AA severity was associated with higher levels of patient-reported disease burden, including anxiety and depression, and work and activity impairment. These data may help inform appropriate treatment strategies.

Indexed as

Alopecia areataBurdenEuropePatient-reported outcomesReal-worldSeveritySymptoms

Identifiers

PMID37889388
PMCPMC10689682
OpenAlexW4387965492

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.